• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications

by jtcir-auto | Jul 31, 2020 | Press Releases

CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...

Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications

by jtcir-auto | Jul 31, 2020 | Press Releases

CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...

AETERNA ZENTARIS ANNOUNCES ABSTRACT OF RESULTS FROM FIRST PEDIATRIC STUDY OF MACIMORELIN ACCEPTED FOR PRESENTATION AT THE 22ND EUROPEAN CONGRESS OF ENDOCRINOLOGY

by jtcir-auto | Jul 30, 2020 | Press Releases

CHARLESTON, S.C., July 30, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the...

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

by jtcir-auto | Jul 29, 2020 | Press Releases

CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic...

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

by jtcir-auto | Jul 29, 2020 | Press Releases

CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic...

AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING

by jtcir-auto | Jul 7, 2020 | Press Releases

CHARLESTON, S.C., July 07, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing...
« Older Entries
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow